Livzon Pharmaceutical Group repurchases A shares, intends to cancel them

Livzon Pharmaceutical Group has disclosed its latest share repurchase activities for its A-shares, which are listed on the Shenzhen Stock Exchange. On September 16, 2025, the company repurchased 92,100 A-shares through other securities exchanges. The repurchases were executed at prices ranging from RMB 39.78 to RMB 40.34 per share, totaling an aggregate cost of RMB 3,691,409. These repurchased shares are currently intended to be cancelled.

The report also detailed numerous A-share repurchases throughout late 2024 and 2025, with individual daily repurchase amounts ranging from 1,700 to 561,400 shares at varying prices. For instance, on December 25, 2024, 145,700 A-shares were repurchased at RMB 37.75, and on January 14, 2025, a significant 561,400 A-shares were bought back at RMB 35.62.

As of September 16, 2025, the company's total issued H-shares (not including treasury shares) remained at 299,807,117. For A-shares, the total issued shares (not including treasury shares) also stood at 604,293,313, with no treasury shares recorded for either class. The company confirmed that all repurchases align with relevant regulations and internal approvals.